Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Solid biosciences - The Untold Story

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

Can Solid Biosciences Challenge Sarepta in the DMD Market?

Can Solid Biosciences Challenge Sarepta in the DMD Market?

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stocks That Hit 52-Week Lows On Friday

During Friday, 125 stocks hit new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

What 4 Analyst Ratings Have To Say About Solid Biosciences

Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.

Recap: Solid Biosciences Q1 Earnings

Recap: Solid Biosciences Q1 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Earnings Outlook For Solid Biosciences

Earnings Outlook For Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Solid Biosciences will report an earnings per share (EPS) of $-0.18.

Solid Biosciences's Return On Capital Employed Insights

Solid Biosciences's Return On Capital Employed Insights

Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter.

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial

Solid Biosciences Inc (NASDAQ:SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DMD. Results suggest durable benefit 24-months post-administration of SGT-001 compared to natural history, consistent with results reported at the 12-month and 18-month…

Recap: Solid Biosciences Q4 Earnings

Recap: Solid Biosciences Q4 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q4 earnings results on Monday, March 14, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

1

Organisations

Lloyds Banking Group

First Republic Bank

Regeneron Pharmaceuticals

Opendoor Technologies

Hims Hers Health

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play